taken from the 2022 annual report:
The broad research partnership is material to Imugene as it includes the development of Imugene’s onCARlytics CD19 oncolytic virus licensed from the City of Hope® with Celularity’s allogeneic CAR T-cell therapy (CyCART-19) and has the potential to become a new approach to improve outcomes for patients with solid tumours.
The research collaboration agreement, effective 5 August 2021, has an initial term of 12 months. Following the successful completion
of the pre-clinical research, the parties will negotiate in good faith a collaboration agreement on commercially reasonable terms.
most likely nothing
Ann: IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT, page-293
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |